Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis
2018 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease,
the most common cause of dementia. Background and context for interpretating the data are con...tained in
the Overview. Additional sections address prevalence, mortality and morbidity, caregiving and use and costs of health care and services. A Special Report discusses the financial and personal benefits of diagnosing earlier in the disease process, in the stage of mild cognitive impairment.
more
This Review summarizes many of the persistent biological alterations associated with childhood maltreatment including changes in neuroendocrine and neurotransmitter systems and pro-inflammatory cytokines in addition to specific alterations in brain areas associated with mood regulation. Finally, I d...iscuss several candidate gene polymorphisms that interact with childhood maltreatment to modulate vulnerability to major depression and PTSD and epigenetic mechanisms thought to transduce environmental stressors into disease vulnerability.
Neuron Review, vol. 89, March 2, 2016 pp.892-909
more
Ein kompakter Ratgeber
23. aktualisierte Auflage
Bei der Bewältigung der Alzheimer-Krankheit und anderer Formen der Demenz müssen viele Personen zusammenwirken: der Patient selbst, seine Angehörigen, Freunde und Bekannte, der Hausarzt und spezialisierte Ärzte, oft auch die Mitarbeiter von Be...ratungsstellen, Tagesstätten und Pflegeeinrichtungen. Sie alle brauchen Informationen über die Krankheit. Das Wichtigste über Demenzerkrankungen zu vermitteln, ist das Ziel des vorliegenden kompakten Ratgebers, den Ihnen die Deutsche Alzheimer Gesellschaft gerne überreicht.
more
November 3, 2009https://doi.org/10.1371/journal.pmed.1000176
PLoS Med 6(11): e1000176. https://doi.org/10.1371/journal.pmed.1000176
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b158 (Published 05 February 2009)
Cite this as: BMJ 2009;338:b158
Correspondence to: A Burns alistair.burns@manchester.ac.uk
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Recommandations francaises pour la prise enc harge du chikungunya
Médecine e tmaladies infectieuses 45(2015)243–263
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Expert Consensus Validation 2018.
This innovative approach aimed at improving and facilitating the screening, prescribing and monitoring of drug therapy for older patients, is currently being further developed in the area of Clinical Pharmacology at the University of Heidelberg in Mannheim. This ap...proach represents another advance in worldwide research efforts aimed at adding a new dimension to already-existing classification systems and negative listings of potentially inappropriate medications for the elderly.
more
Zhou et al. Int J Ment Health Syst (2019) 13:10 https://doi.org/10.1186/s13033-019-0263-1